Mount Prospect

Researchers are evaluating the efficacy and safety of the drug levosimendan, taken orally, compared to a placebo in adults with pulmonary hypertension associated with heart failure with preserved left ventricular ejection fraction PH-HFpEF. The main goal is to measure the change in the 6-Minute Walk Distance, which reflects exercise capacity. This phase 3, randomized, double-blind study aims to improve understanding of treatment options for this condition. About 540 participants will be randomly assigned in a 21 ratio to receive either oral levosimendan or a matching placebo. Those who complete the initial study period of 26 weeks may be eligible to join an open-label extension lasting 52 weeks, during which all participants can receive levosimendan. The study carefully monitors participants throughout both phases to assess the effects of the treatment. Participants will undergo various assessments including the 6-Minute Walk Distance test, questionnaires like the Kansas City Cardiomyopathy Questionnaire to evaluate health status, and classification of physical ability using the New York Heart Association scale. Screening includes heart catheterization, echocardiograms, ambulatory heart rhythm monitoring, and exercise testing. Safety and clinical worsening events will be tracked. The total involvement may last beyond a year for those in the extension phase, ensuring thorough evaluation of outcomes and safety.

This research aims to collect urine and tumor samples along with clinical data from patients being evaluated, treated, or monitored for urothelial carcinoma, including bladder cancer. It is a prospective, multicenter observational study designed to validate a new testing platform called UroAmp for detecting and surveilling bladder cancer and related conditions. Participants provide a urine sample at enrollment using a proprietary urine collection system. They are then followed for up to five years, during which urine samples, tissue samples when applicable, and clinical information are collected during their routine care visits. The study includes two groups patients with bladder or upper tract urothelial carcinoma and hematuria controls without cancer history. Participants will be involved in regular clinical visits as part of their standard care, during which samples and data are collected. Researchers will measure outcomes such as recurrence-free survival and diagnostic accuracy for hematuria evaluation over up to five years. The study also compares UroAmp to other urine biomarkers and assesses early detection of cancer recurrence, ensuring ongoing monitoring and data collection throughout the follow-up period.